博济医药(.SZ)2023年报&2024年一季报业绩解读会

Key Points Summary Company and Industry - The conference call pertains to Open Source Pharmaceuticals and its performance in the pharmaceutical industry for the year 2023 and projections for 2024 [1] Core Insights and Arguments - The meeting is focused on the 2023 annual report and the 2024 first-level report performance interpretation [1] - The audience consists of elite participants from professional investment institutions, indicating a targeted approach to engage knowledgeable investors [1] Other Important but Potentially Overlooked Content - A disclaimer was read at the beginning of the meeting, which is a standard practice to inform participants about the nature of the information being discussed [1]